Pharmacopeia Drug Discovery Earns Milestone Payment From Schering-Plough Corporation As Novel Therapeutic Candidate Enters Phase I Clinical Trial

PRINCETON, N.J., Sept. 11 /PRNewswire-FirstCall/ -- Pharmacopeia (Nasdaq: PCOP - News), an innovator in the discovery and development of novel small molecule therapeutics, today announced that Schering-Plough has initiated a Phase I clinical trial in the United States with a new compound identified from the Pharmacopeia - Schering-Plough collaboration in the oncology therapeutic area.